Sunshine Heart Inc (CHFS) Major Shareholder Buys $50,055.04 in Stock
Sunshine Heart Inc (NASDAQ:CHFS) major shareholder Ki Yong Choi bought 78,211 shares of Sunshine Heart stock in a transaction that occurred on Wednesday, September 13th. The shares were acquired at an average cost of $0.64 per share, for a total transaction of $50,055.04. Following the acquisition, the insider now owns 1,731,464 shares in the company, valued at approximately $1,108,136.96. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Sunshine Heart Inc (NASDAQ:CHFS) traded down 0.2333% during trading on Friday, hitting $0.5986. 201,865 shares of the company traded hands. Sunshine Heart Inc has a 52 week low of $0.51 and a 52 week high of $28.80. The stock’s market capitalization is $7.49 million. The company’s 50 day moving average is $0.69 and its 200-day moving average is $1.26.
ILLEGAL ACTIVITY NOTICE: “Sunshine Heart Inc (CHFS) Major Shareholder Buys $50,055.04 in Stock” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/23/sunshine-heart-inc-chfs-major-shareholder-buys-50055-04-in-stock.html.
CHFS has been the topic of several recent research reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Sunshine Heart in a report on Thursday, June 29th. They set a “buy” rating and a $3.25 target price on the stock. ValuEngine raised shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
Sunshine Heart Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Receive News & Ratings for Sunshine Heart Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart Inc and related companies with MarketBeat.com's FREE daily email newsletter.